TG Therapeutics Inc (TGTX)

Receivables turnover

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Revenue (ttm)	US$ in thousands	262,359	340,582	280,254	222,343	180,883	18,875	6,331	2,784	5,025	6,961	7,912	6,689	4,406	2,414	907	152	152	152	152	152
Receivables	US$ in thousands	115,727	83,608	64,982	51,093	39,320	17,484	8,623	0	—	88	903	1,389	1,384	931	771	—	—	—	—	—
Receivables turnover		2.27	4.07	4.31	4.35	4.60	1.08	0.73	—	—	79.10	8.76	4.82	3.18	2.59	1.18	—	—	—	—	—

September 30, 2024 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $262,359K ÷ $115,727K
= 2.27

TG Therapeutics Inc's receivables turnover ratio has been fluctuating over the past few quarters. For the most recent quarter ending September 30, 2024, the receivables turnover ratio stands at 2.27, indicating that the company collected its accounts receivable approximately 2.27 times during that period.

The trend in receivables turnover shows improvement compared to the prior quarter. However, the ratio is still relatively lower than previous periods in 2023 when it ranged between 4.07 to 4.60. The significant drop in the receivables turnover for the quarter ending June 30, 2022, when it was 79.10, could potentially indicate an anomaly or a specific event impacting the collections during that period.

Overall, the lower receivables turnover ratios suggest that the company may be taking longer to collect its outstanding receivables, which could potentially impact its liquidity and cash flow management. It would be beneficial for TG Therapeutics Inc to closely monitor and improve its collection processes to ensure timely inflow of cash from its sales.